This site is intended for healthcare professionals

IPF Hero banner

Idiopathic Pulmonary Fibrosis (IPF) Learning Zone

Declaration of sponsorship

Expert Opinion

Declaration of sponsorship

Read time: 20 mins

Last updated:19th Apr 2024

Published:29th Jan 2020

Professor Elisabeth Bendstrup

Senior consultant and associate professor at the Department of Respiratory Diseases and Allergy at Aarhus University Hospital, Denmark. She is head of the hospital’s ILD unit (the Danish Centre for Interstitial Lung Diseases and Sarcoidosis), which is a tertiary referral centre for ILD and sarcoidosis.

Find out how Professor Bendstrup answered our questions related to caring for patients with IPF.

Professor Bendstrup also features in our EACCME^® accredited CME module: Recognising and optimising care of IPF - click here to access the learning’

Why do you, personally, feel that IPF is such an important and fascinating disease

Why do you, personally, feel that IPF is such an important and fascinating disease?

1

next video Do you have an example of how anti-fibrotic treatment has improved patient quality of life?

Do you have an example of how anti-fibrotic treatment has improved patient quality of life

Do you have an example of how anti-fibrotic treatment has improved patient quality of life?

1

next video Do you feel that the identification of genetic polymorphisms and other biomarkers will help improve the diagnosis of IPF? If so, how?

Do you feel that the identification of genetic polymorphisms and other biomarkers will help improve the diagnosis of IPF If so, how

Do you feel that the identification of genetic polymorphisms and other biomarkers will help improve the diagnosis of IPF? If so, how?

1

next video What would you say to a GP or non-specialist who feels that they have higher priorities (e.g. more common diseases) than maintaining an index of suspicion for rare diseases such as IPF?

What would you say to a GP or non-specialist who feels that they have higher priorities (e.g. more common diseases) than maintaining an index of

What would you say to a GP or non-specialist who feels that they have higher priorities (e.g. more common diseases) than maintaining an index of suspicion for rare diseases such as IPF?

1

next video Why do you feel drugs targeting several biologically plausible mechanisms have not translated into recommended treatments?

Why do you feel drugs targeting several biologically plausible mechanisms have not translated into recommended treatments

Why do you feel drugs targeting several biologically plausible mechanisms have not translated into recommended treatments?

1

next video Is it a poor understanding of the disease or poorly designed studies?

Is it a poor understanding of the disease or poorly designed studies

Is it a poor understanding of the disease or poorly designed studies?

1

next video What do you think is really important for physicians to know about IPF?

What do you think is really important for physicians to know about IPF

What do you think is really important for physicians to know about IPF?

1

next video What has been your highlight of the ERS Congress 2019?

What has been your highlight of the ERS Congress 2019

What has been your highlight of the ERS Congress 2019?

1

Professor Kristin Highland

Associate Program Director for Research and Scholarly Activity and Director of the Rheumatic Lung Disease Programme and an active member of the Interstitial Lung Disease and Pulmonary Hypertension programmes at the Cleveland clinic/Respiratory Institute, Ohio, US.

Find out how Professor Highland answered our questions related to caring for patients with autoimmune ILD.

Why do you, personally, enjoy working in this specialty

Why do you, personally, enjoy working in this specialty?

1

next video Do the results of histopathology alter management of autoimmune ILD?

Do the results of histopathology alter management of autoimmune ILD

Do the results of histopathology alter management of autoimmune ILD?

2

next video A relatively high proportion of patients develop ILD in some subtypes of CTD. Is this risk adequately appreciated among clinicians managing the underlying autoimmune condition?

A relatively high proportion of patients develop ILD in some subtypes of CTD. Is this risk adequately appreciated among clinicians managing

A relatively high proportion of patients develop ILD in some subtypes of CTD. Is this risk adequately appreciated among clinicians managing the underlying autoimmune condition?

1

next video Is screening for lung disease adequate in people with autoimmune diseases?

Is screening for lung disease adequate in people with autoimmune diseases

Is screening for lung disease adequate in people with autoimmune diseases?

1

next video What is the most important diagnostic or screening need in autoimmune-ILD either for a specific condition or for the group?

What is the most important diagnostic or screening need in autoimmune-ILD either for a specific condition or for the group

What is the most important diagnostic or screening need in autoimmune-ILD either for a specific condition or for the group?

1

next video Why does ILD often progress when other aspects of the underlying autoimmune disease seem to be well controlled?

Why does ILD often progress when other aspects of the underlying autoimmune disease seem to be well controlled

Why does ILD often progress when other aspects of the underlying autoimmune disease seem to be well controlled?

2

next video Are there any clinical features (e.g. temporality) that might help differentiate adverse events from ILD?

Are there any clinical features (e.g. temporality) that might help differentiate adverse events from ILD

Are there any clinical features (e.g. temporality) that might help differentiate adverse events from ILD?

1

next video Is there anything else that you think is really important for physicians to know about ILD?

Is there anything else that you think is really important for physicians to know about ILD

Is there anything else that you think is really important for physicians to know about ILD?

2

Professor Highland also features in our EACCME accredited CME module: Recognising and treating autoimmune ILDs – click here to access

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event